keyword
MENU ▼
Read by QxMD icon Read
search

govindan ramaswamy

keyword
https://www.readbyqxmd.com/read/27912831/systemic-treatment-of-brain-metastases
#1
REVIEW
Saiama N Waqar, Daniel Morgensztern, Ramaswamy Govindan
Lung cancer continues to be the leading cause of cancer-related mortality in the United States. Brain metastases are a significant problem in patients with lung cancer and have conventionally been treated with whole-brain radiation. This article reviews the data for systemic chemotherapy to treat brain metastasis from lung cancer and examines the activity of small molecule tyrosine kinase inhibitors for the targeted therapy for brain metastases from EGFR-mutant and ALK-rearranged non-small cell lung cancer...
February 2017: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/27912825/next-generation-sequencing-of-lung-cancers-lessons-learned-and-future-directions
#2
REVIEW
Siddhartha Devarakonda, Ashiq Masood, Ramaswamy Govindan
Targeted therapies and immune checkpoint inhibitors have significantly improved outcomes in a sizable fraction of patients with metastatic non-small cell lung cancer. Nevertheless, a majority of patients with lung cancer continue to have poor outcomes. The ability to comprehensively characterize the genomic alterations in various subtypes of lung cancer has the potential to transform cancer care by facilitating the identification of novel treatment strategies. The objective of this review is to summarize key findings from recent studies that have sequenced a large number of lung cancer samples and discuss the diagnostic, prognostic, and therapeutic relevance of these findings...
February 2017: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/27863201/pooled-analysis-of-cns-response-to-alectinib-in-two-studies-of-pretreated-patients-with-alk-positive-non-small-cell-lung-cancer
#3
Shirish M Gadgeel, Alice T Shaw, Ramaswamy Govindan, Leena Gandhi, Mark A Socinski, D Ross Camidge, Luigi De Petris, Dong-Wan Kim, Alberto Chiappori, Denis L Moro-Sibilot, Michael Duruisseaux, Lucio Crino, Tommaso De Pas, Eric Dansin, Antje Tessmer, James Chih-Hsin Yang, Ji-Youn Han, Walter Bordogna, Sophie Golding, Ali Zeaiter, Sai-Hong Ignatius Ou
Purpose Alectinib has shown activity in the CNS in phase I and II studies. To further evaluate this activity, we pooled efficacy and safety data from two single-arm phase II studies (NP28761 and NP28673; ClinicalTrials.gov identifiers: NCT01871805 and NCT01801111, respectively) in patients with ALK-positive non-small-cell lung cancer (NSCLC). Patients and Methods Both studies included patients with ALK-positive NSCLC who had previously received crizotinib; all patients received alectinib 600 mg twice per day...
December 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27697581/brief-report-phase-i-results-from-a-study-of-crizotinib-in-combination-with-erlotinib-in-patients-with-advanced-non-squamous-non-small-cell-lung-cancer
#4
Sai-Hong Ignatius Ou, Ramaswamy Govindan, Keith D Eaton, Gregory A Otterson, Martin E Gutierrez, Alain C Mita, Athanassios Argiris, Nicoletta M Brega, Tiziana Usari, Weiwei Tan, Steffan N Ho, Francisco Robert
INTRODUCTION: This phase I trial was conducted to determine the safety, maximum tolerated dose (MTD)/recommended phase II dose, and efficacy of crizotinib plus erlotinib in patients with advanced non-squamous non-small cell lung cancer (NSCLC). METHODS: NSCLC patients with an Eastern Cooperative Oncology Group performance status of 0-2 after failure of 1-2 prior chemotherapy regimens were eligible. Erlotinib 100 mg was given continuously once daily (QD) starting between day -14 and -7; crizotinib 200 mg twice daily (BID; dose level 1) or 150 mg BID (dose level -1) was added continuously beginning on treatment cycle 1, day 1...
September 30, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27461773/efficacy-and-safety-results-from-a-phase-ii-placebo-controlled-study-of-onartuzumab-plus-first-line-platinum-doublet-chemotherapy-for-advanced-squamous-cell-non-small-cell-lung-cancer
#5
Fred R Hirsch, Ramaswamy Govindan, Zanete Zvirbule, Fadi Braiteh, Achim Rittmeyer, Cristóbal Belda-Iniesta, Dolores Isla, Thomas Cosgriff, Michelle Boyer, Masamichi Ueda, See Phan, David R Gandara
INTRODUCTION: The treatment options for squamous cell non-small-cell lung cancer (NSCLC) are limited. We assessed the efficacy and safety of onartuzumab plus platinum-doublet chemotherapy in previously untreated advanced squamous cell NSCLC. PATIENTS AND METHODS: The patients were randomized to receive onartuzumab plus paclitaxel plus carboplatin/cisplatin (n = 55) or placebo plus paclitaxel plus carboplatin/cisplatin (n = 54). Randomization was stratified by MET diagnostic status: MET immunohistochemistry (IHC)-positive (MET IHC 3+/2+) or MET IHC-negative (MET IHC 1+/0)...
June 4, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/27407123/nccn-guidelines-insights-malignant-pleural-mesothelioma-version-3-2016
#6
David S Ettinger, Douglas E Wood, Wallace Akerley, Lyudmila A Bazhenova, Hossein Borghaei, David Ross Camidge, Richard T Cheney, Lucian R Chirieac, Thomas A D'Amico, Thomas Dilling, Michael Dobelbower, Ramaswamy Govindan, Mark Hennon, Leora Horn, Thierry M Jahan, Ritsuko Komaki, Rudy P Lackner, Michael Lanuti, Rogerio Lilenbaum, Jules Lin, Billy W Loo, Renato Martins, Gregory A Otterson, Jyoti D Patel, Katherine M Pisters, Karen Reckamp, Gregory J Riely, Steven E Schild, Theresa A Shapiro, Neelesh Sharma, Scott J Swanson, James Stevenson, Kurt Tauer, Stephen C Yang, Kristina Gregory, Miranda Hughes
These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for Malignant Pleural Mesothelioma (MPM). These NCCN Guidelines Insights discuss systemic therapy regimens and surgical controversies for MPM. The NCCN panel recommends cisplatin/pemetrexed (category 1) for patients with MPM. The NCCN panel also now recommends bevacizumab/cisplatin/pemetrexed as a first-line therapy option for patients with unresectable MPM who are candidates for bevacizumab. The complete version of the NCCN Guidelines for MPM, available at NCCN...
July 2016: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/27401214/clinician-perspectives-on-current-issues-in-lung-cancer-drug-development
#7
REVIEW
Saiama N Waqar, Philip D Bonomi, Ramaswamy Govindan, Fred R Hirsch, Gregory J Riely, Vassiliki Papadimitrakopoulou, Dickran Kazandjian, Sean Khozin, Erin Larkins, Dane J Dickson, Shakun Malik, Leora Horn, Andrea Ferris, Alice T Shaw, Pasi A Jänne, Tony S K Mok, Roy Herbst, Patricia Keegan, Richard Pazdur, Gideon M Blumenthal
Recent advances in molecularly targeted therapy and immunotherapy offer a glimmer of hope for potentially realizing the dream of personalized therapy for lung cancer. This article highlights current questions in clinical trial design, enrollment strategies and patient focused drug development, with particular emphasis on unique issues in trials of targeted therapy and immunotherapy.
September 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27287414/adjuvant-chemotherapy-for-patients-with-t2n0m0-nsclc
#8
Daniel Morgensztern, Lingling Du, Saiama N Waqar, Aalok Patel, Pamela Samson, Siddhartha Devarakonda, Feng Gao, Cliff G Robinson, Jeffrey Bradley, Maria Baggstrom, Ashiq Masood, Ramaswamy Govindan, Varun Puri
BACKGROUND: Adjuvant chemotherapy improves survival in patients with completely resected stage II and III NSCLC. However, its role in patients with stage IB NSCLC disease remains unclear. We evaluated the role of adjuvant chemotherapy in a large data set of patients with completely resected T2N0M0 NSCLC. METHODS: Patients with pathologic stage T2N0M0 NSCLC who underwent complete (R0) resection between 2004 and 2011 were identified from the National Cancer Data Base and classified into four groups based on tumor size: 3...
October 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27194218/nutritional-properties-of-the-largest-bamboo-fruit-melocanna-baccifera-and-its-ecological-significance
#9
Balaji Govindan, Anil John Johnson, Sadasivan Nair Ajikumaran Nair, Bhaskaran Gopakumar, Karuna Sri Lakshmi Mallampalli, Ramaswamy Venkataraman, Konnath Chacko Koshy, Sabulal Baby
Melocanna baccifera is a unique bamboo which produces the largest fruits in the grass family. Its gregarious flowering once in 45-50 years in north east India and adjacent regions is a botanical enigma, resulting in a glut of fruits. Proper utilization of M. baccifera fruits is not extant, and huge quantities of fruits are left underexploited due to lack of scientific information on their chemical composition and nutritional potential. Here we report the nutritional properties of M. baccifera fruits, and the ecological significance of its fruiting...
2016: Scientific Reports
https://www.readbyqxmd.com/read/27168435/clinical-implications-of-genomic-discoveries-in-lung-cancer
#10
REVIEW
Charles Swanton, Ramaswamy Govindan
No abstract text is available yet for this article.
May 12, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/27158780/distinct-patterns-of-somatic-genome-alterations-in-lung-adenocarcinomas-and-squamous-cell-carcinomas
#11
Joshua D Campbell, Anton Alexandrov, Jaegil Kim, Jeremiah Wala, Alice H Berger, Chandra Sekhar Pedamallu, Sachet A Shukla, Guangwu Guo, Angela N Brooks, Bradley A Murray, Marcin Imielinski, Xin Hu, Shiyun Ling, Rehan Akbani, Mara Rosenberg, Carrie Cibulskis, Aruna Ramachandran, Eric A Collisson, David J Kwiatkowski, Michael S Lawrence, John N Weinstein, Roel G W Verhaak, Catherine J Wu, Peter S Hammerman, Andrew D Cherniack, Gad Getz, Maxim N Artyomov, Robert Schreiber, Ramaswamy Govindan, Matthew Meyerson
To compare lung adenocarcinoma (ADC) and lung squamous cell carcinoma (SqCC) and to identify new drivers of lung carcinogenesis, we examined the exome sequences and copy number profiles of 660 lung ADC and 484 lung SqCC tumor-normal pairs. Recurrent alterations in lung SqCCs were more similar to those of other squamous carcinomas than to alterations in lung ADCs. New significantly mutated genes included PPP3CA, DOT1L, and FTSJD1 in lung ADC, RASA1 in lung SqCC, and KLF5, EP300, and CREBBP in both tumor types...
June 2016: Nature Genetics
https://www.readbyqxmd.com/read/27145068/delayed-nausea-and-vomiting-from-carboplatin-doublet-chemotherapy
#12
Saiama N Waqar, Janelle Mann, Maria Q Baggstrom, Muhammad Atif Waqar, Pooja Chitneni, Kristina Williams, Feng Gao, Daniel Morgensztern, Ramaswamy Govindan
BACKGROUND: Delayed nausea and vomiting following administration of carboplatin containing chemotherapy regimen remains a clinically significant problem for patients with cancer despite administration of standard antiemetic prophylaxis comprising of a 5-HT3 antagonist and dexamethasone. We performed a prospective study to define the incidence and risk factors for delayed chemotherapy-induced nausea and vomiting (CINV). METHODS: Previously untreated patients with newly diagnosed cancer scheduled to receive carboplatin containing chemotherapy (AUC 5 or above), but no prophylactic aprepitant were enrolled in the study...
June 2016: Acta Oncologica
https://www.readbyqxmd.com/read/26957612/nccn-guidelines-insights-non-small-cell-lung-cancer-version-4-2016
#13
David S Ettinger, Douglas E Wood, Wallace Akerley, Lyudmila A Bazhenova, Hossein Borghaei, David Ross Camidge, Richard T Cheney, Lucian R Chirieac, Thomas A D'Amico, Thomas J Dilling, M Chris Dobelbower, Ramaswamy Govindan, Mark Hennon, Leora Horn, Thierry M Jahan, Ritsuko Komaki, Rudy P Lackner, Michael Lanuti, Rogerio Lilenbaum, Jules Lin, Billy W Loo, Renato Martins, Gregory A Otterson, Jyoti D Patel, Katherine M Pisters, Karen Reckamp, Gregory J Riely, Steven E Schild, Theresa A Shapiro, Neelesh Sharma, James Stevenson, Scott J Swanson, Kurt Tauer, Stephen C Yang, Kristina Gregory, Miranda Hughes
These NCCN Guidelines Insights focus on recent updates in the 2016 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC; Versions 1-4). These NCCN Guidelines Insights will discuss new immunotherapeutic agents, such as nivolumab and pembrolizumab, for patients with metastatic NSCLC. For the 2016 update, the NCCN panel recommends immune checkpoint inhibitors as preferred agents (in the absence of contraindications) for second-line and beyond (subsequent) therapy in patients with metastatic NSCLC (both squamous and nonsquamous histologies)...
March 2016: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/26829312/small-cell-lung-cancer-can-recent-advances-in-biology-and-molecular-biology-be-translated-into-improved-outcomes
#14
REVIEW
Paul A Bunn, John D Minna, Alexander Augustyn, Adi F Gazdar, Youcef Ouadah, Mark A Krasnow, Anton Berns, Elisabeth Brambilla, Natasha Rekhtman, Pierre P Massion, Matthew Niederst, Martin Peifer, Jun Yokota, Ramaswamy Govindan, John T Poirier, Lauren A Byers, Murry W Wynes, David G McFadden, David MacPherson, Christine L Hann, Anna F Farago, Caroline Dive, Beverly A Teicher, Craig D Peacock, Jane E Johnson, Melanie H Cobb, Hans-Guido Wendel, David Spigel, Julien Sage, Ping Yang, M Catherine Pietanza, Lee M Krug, John Heymach, Peter Ujhazy, Caicun Zhou, Koichi Goto, Afshin Dowlati, Camilla Laulund Christensen, Keunchil Park, Lawrence H Einhorn, Martin J Edelman, Giuseppe Giaccone, David E Gerber, Ravi Salgia, Taofeek Owonikoko, Shakun Malik, Niki Karachaliou, David R Gandara, Ben J Slotman, Fiona Blackhall, Glenwood Goss, Roman Thomas, Charles M Rudin, Fred R Hirsch
No abstract text is available yet for this article.
April 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/26811519/proclaim-randomized-phase-iii-trial-of-pemetrexed-cisplatin-or-etoposide-cisplatin-plus-thoracic-radiation-therapy-followed-by-consolidation-chemotherapy-in-locally-advanced-nonsquamous-non-small-cell-lung-cancer
#15
RANDOMIZED CONTROLLED TRIAL
Suresh Senan, Anthony Brade, Lu-Hua Wang, Johan Vansteenkiste, Shaker Dakhil, Bonne Biesma, Maite Martinez Aguillo, Joachim Aerts, Ramaswamy Govindan, Belén Rubio-Viqueira, Conrad Lewanski, David Gandara, Hak Choy, Tony Mok, Anwar Hossain, Neill Iscoe, Joseph Treat, Andrew Koustenis, Bélen San Antonio, Nadia Chouaki, Everett Vokes
PURPOSE: The phase III PROCLAIM study evaluated overall survival (OS) of concurrent pemetrexed-cisplatin and thoracic radiation therapy (TRT) followed by consolidation pemetrexed, versus etoposide-cisplatin and TRT followed by nonpemetrexed doublet consolidation therapy. PATIENTS AND METHODS: Patients with stage IIIA/B unresectable nonsquamous non-small-cell lung cancer randomly received (1:1) pemetrexed 500 mg/m(2) and cisplatin 75 mg/m(2) intravenously every 3 weeks for three cycles plus concurrent TRT (60 to 66 Gy) followed by pemetrexed consolidation every 3 weeks for four cycles (arm A), or standard therapy with etoposide 50 mg/m(2) and cisplatin 50 mg/m(2) intravenously, every 4 weeks for two cycles plus concurrent TRT (60 to 66 Gy) followed by two cycles of consolidation platinum-based doublet chemotherapy (arm B)...
March 20, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/26780363/a-phase-i-trial-of-temsirolimus-and-pemetrexed-in-patients-with-advanced-non-small-cell-lung-cancer
#16
Saiama N Waqar, Maria Q Baggstrom, Daniel Morgensztern, Kristina Williams, Caron Rigden, Ramaswamy Govindan
BACKGROUND: Pemetrexed is an antifolate chemotherapeutic agent approved for use in non-small cell lung cancer (NSCLC). The mammalian target of rapamycin (mTOR) pathway is implicated in lung cancer development and inhibited by temsirolimus. METHODS: We performed a phase I study evaluating the combination of pemetrexed and temsirolimus in advanced non-squamous NSCLC. RESULTS: Eight patients were enrolled in this study. The dose-limiting toxicities included grade 4 thrombocytopenia, grade 3 leukopenia and grade 3 neutropenia...
2016: Chemotherapy
https://www.readbyqxmd.com/read/26689913/patterns-and-functional-implications-of-rare-germline-variants-across-12-cancer-types
#17
Charles Lu, Mingchao Xie, Michael C Wendl, Jiayin Wang, Michael D McLellan, Mark D M Leiserson, Kuan-Lin Huang, Matthew A Wyczalkowski, Reyka Jayasinghe, Tapahsama Banerjee, Jie Ning, Piyush Tripathi, Qunyuan Zhang, Beifang Niu, Kai Ye, Heather K Schmidt, Robert S Fulton, Joshua F McMichael, Prag Batra, Cyriac Kandoth, Maheetha Bharadwaj, Daniel C Koboldt, Christopher A Miller, Krishna L Kanchi, James M Eldred, David E Larson, John S Welch, Ming You, Bradley A Ozenberger, Ramaswamy Govindan, Matthew J Walter, Matthew J Ellis, Elaine R Mardis, Timothy A Graubert, John F Dipersio, Timothy J Ley, Richard K Wilson, Paul J Goodfellow, Benjamin J Raphael, Feng Chen, Kimberly J Johnson, Jeffrey D Parvin, Li Ding
Large-scale cancer sequencing data enable discovery of rare germline cancer susceptibility variants. Here we systematically analyse 4,034 cases from The Cancer Genome Atlas cancer cases representing 12 cancer types. We find that the frequency of rare germline truncations in 114 cancer-susceptibility-associated genes varies widely, from 4% (acute myeloid leukaemia (AML)) to 19% (ovarian cancer), with a notably high frequency of 11% in stomach cancer. Burden testing identifies 13 cancer genes with significant enrichment of rare truncations, some associated with specific cancers (for example, RAD51C, PALB2 and MSH6 in AML, stomach and endometrial cancers, respectively)...
2015: Nature Communications
https://www.readbyqxmd.com/read/26672084/alchemist-trials-a-golden-opportunity-to-transform-outcomes-in-early-stage-non-small-cell-lung-cancer
#18
REVIEW
Ramaswamy Govindan, Sumithra J Mandrekar, David E Gerber, Geoffrey R Oxnard, Suzanne E Dahlberg, Jamie Chaft, Shakun Malik, Margaret Mooney, Jeffrey S Abrams, Pasi A Jänne, David R Gandara, Suresh S Ramalingam, Everett E Vokes
The treatment of patients with metastatic non-small cell lung cancer (NSCLC) is slowly evolving from empirical cytotoxic chemotherapy to personalized treatment based on specific molecular alterations. Despite this 10-year evolution, targeted therapies have not been studied adequately in patients with resected NSCLC who have clearly defined actionable mutations. The advent of next-generation sequencing has now made it possible to characterize genomic alterations in unprecedented detail. The efforts begun by The Cancer Genome Atlas project to understand the complexities of the genomic landscape of lung cancer will be supplemented further by studying a large number of tumor specimens...
December 15, 2015: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/26669741/immunogenicity-of-influenza-vaccination-in-patients-with-cancer
#19
Saiama N Waqar, Leigh Boehmer, Daniel Morgensztern, Andrea Wang-Gillam, Steven Sorscher, Steven Lawrence, Feng Gao, Kalin Guebert, Kristina Williams, Ramaswamy Govindan
BACKGROUND: Influenza leads to significant morbidity and mortality in patients with cancer. Patients with cancer receiving chemotherapy may not mount an adequate immune response to the vaccine. We performed this pilot study to evaluate the immunogenicity of influenza vaccination in patients with cancer receiving chemotherapy. MATERIALS AND METHODS: During the 2011 to 2012 influenza season, patients undergoing chemotherapy for solid tumors were given trivalent inactivated influenza vaccine either on the day of chemotherapy (schedule A) or a week before chemotherapy (schedule B) by a single 0...
December 14, 2015: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/26598747/alectinib-in-crizotinib-refractory-alk-rearranged-non-small-cell-lung-cancer-a-phase-ii-global-study
#20
MULTICENTER STUDY
Sai-Hong Ignatius Ou, Jin Seok Ahn, Luigi De Petris, Ramaswamy Govindan, James Chih-Hsin Yang, Brett Hughes, Hervé Lena, Denis Moro-Sibilot, Alessandra Bearz, Santiago Viteri Ramirez, Tarek Mekhail, Alexander Spira, Walter Bordogna, Bogdana Balas, Peter N Morcos, Annabelle Monnet, Ali Zeaiter, Dong-Wan Kim
PURPOSE: Crizotinib confers improved progression-free survival compared with chemotherapy in anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC), but progression invariably occurs. We investigated the efficacy and safety of alectinib, a potent and selective ALK inhibitor with excellent CNS penetration, in patients with crizotinib-refractory ALK-positive NSCLC. PATIENTS AND METHODS: Alectinib 600 mg was administered orally twice daily. The primary end point was objective response rate (ORR) by central independent review committee (IRC)...
March 1, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
keyword
keyword
119319
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"